Sectors & IndustriesHealthcareBiotechnology
Best Biotech Stocks to Buy Now (2025)
Top biotech stocks in 2025 ranked by overall Due Diligence Score. See the best biotech stocks to buy now, according to analyst forecasts for the biotechnology industry.

Industry: Biotechnology
Ticker
Company
Forecast Score
Market Cap
Price
Price Target
Upside/Downside
Top Analysts Upside/Downside
Consensus
Top Analysts Consensus
Analysts
Top Analysts
Fore. Revenue Growth
Fore. Earnings Growth
Forecast ROE
Forecast ROA
CPRX
CATALYST PHARMACEUTICALS INC
$2.75B$23.06$32.5040.94%Strong Buy615.76%26.55%48.00%41.10%
EXEL
EXELIXIS INC
$9.62B$33.67$36.809.30%Buy1511.07%25.87%45.39%34.89%
HRMY
HARMONY BIOSCIENCES HOLDINGS INC
$2.21B$38.78$56.0044.40%Strong Buy721.37%39.52%67.18%43.20%
CORT
CORCEPT THERAPEUTICS INC
$7.13B$68.04$88.2529.70%Strong Buy422.70%43.53%79.63%64.86%
RPRX
ROYALTY PHARMA PLC
$18.50B$31.40$45.5044.90%Strong Buy230.86%69.55%27.57%15.67%
HALO
HALOZYME THERAPEUTICS INC
$7.37B$57.94$62.387.65%Buy822.21%38.18%250.55%53.55%
KRYS
KRYSTAL BIOTECH INC
$4.63B$161.06$213.0032.25%Buy549.80%74.28%31.69%28.58%
ADMA
ADMA BIOLOGICS INC
$4.00B$16.92$23.6739.88%Strong Buy322.90%53.60%137.62%81.70%
GMAB
GENMAB A
$12.80B$19.35$44.75131.27%Buy421.21%41.53%5.49%4.42%
ACAD
ACADIA PHARMACEUTICALS INC
$3.18B$19.13$24.3827.42%Buy811.71%37.49%69.38%40.99%
SRPT
SAREPTA THERAPEUTICS INC
$10.71B$112.11$159.5442.30%Buy1340.68%122.22%149.88%50.84%
BMRN
BIOMARIN PHARMACEUTICAL INC
$12.26B$64.34$91.7842.65%Strong Buy1811.07%49.35%N/AN/A
UTHR
UNITED THERAPEUTICS CORP
$15.79B$353.75$417.5618.04%Strong Buy99.45%6.79%27.02%23.14%
LGND
LIGAND PHARMACEUTICALS INC
$2.23B$117.84$148.4025.93%Strong Buy519.60%25.10%12.00%10.57%
VCEL
VERICEL CORP
$2.95B$59.70$64.177.48%Strong Buy628.06%163.52%36.52%24.08%
GNFT
GENFIT SA
$199.38M$4.00$13.00225.41%Buy125.32%-54.80%-40.58%-20.29%
AGIO
AGIOS PHARMACEUTICALS INC
$1.96B$34.42$59.7573.59%Buy4124.82%N/A3.65%3.31%
REGN
REGENERON PHARMACEUTICALS INC
$78.94B$722.07$944.3230.78%Buy196.08%11.19%22.23%17.28%
DNTH
DIANTHUS THERAPEUTICS INC
$679.55M$22.96$46.00100.35%Buy467.58%N/A-23.42%-22.34%
KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL PLC
$1.46B$20.29$38.3388.93%Strong Buy328.76%N/A27.59%21.71%
NVO
NOVO NORDISK A S
$389.21B$87.17$132.5052.00%Strong Buy215.54%18.69%127.00%39.12%
PBYI
PUMA BIOTECHNOLOGY INC
$141.86M$2.89$7.00142.21%Buy1-4.97%-20.83%33.49%10.79%
INCY
INCYTE CORP
$14.44B$74.95$76.001.40%Buy1311.20%267.39%60.72%38.42%
CDXC
CHROMADEX CORP
$434.62M$5.69$8.0040.60%Strong Buy231.78%1,100.00%37.78%22.97%
ROIV
ROIVANT SCIENCES LTD
$7.91B$10.87$15.2540.29%Buy2-22.82%N/AN/AN/A
CVAC
CUREVAC NV
$836.78M$3.73$16.00328.95%Buy1-28.46%-7.30%7.27%6.17%
TRDA
ENTRADA THERAPEUTICS INC
$504.42M$13.48$25.6790.41%Strong Buy311.08%N/A41.54%31.64%
MDXG
MIMEDX GROUP INC
$1.25B$8.50N/AN/AN/AN/A12.98%3.62%N/AN/A
DTIL
PRECISION BIOSCIENCES INC
$37.43M$4.88$47.00863.11%Buy21.12%23.93%4.73%2.00%
KPRX
KIORA PHARMACEUTICALS INC
$11.07M$3.69$10.00171.00%Buy1N/AN/AN/AN/A
JAZZ
JAZZ PHARMACEUTICALS PLC
$7.26B$120.07$179.0049.08%Strong Buy77.08%34.56%N/AN/A
PTGX
PROTAGONIST THERAPEUTICS INC
$2.25B$37.75$55.8647.97%Strong Buy7-23.36%N/A16.27%14.34%
VYNE
VYNE THERAPEUTICS INC
$35.70M$2.42$6.88184.09%Strong Buy2332.24%N/A-38.31%-31.94%
FULC
FULCRUM THERAPEUTICS INC
$206.59M$3.83$3.40-11.23%Hold524.59%N/A-17.61%-16.24%
VTGN
VISTAGEN THERAPEUTICS INC
$79.91M$2.87N/AN/AN/AN/A68.28%N/A-73.07%-66.28%
TGTX
TG THERAPEUTICS INC
$5.21B$33.50$40.8021.79%Strong Buy554.04%N/A311.89%102.27%
APRE
APREA THERAPEUTICS INC
$21.60M$3.98$15.50289.94%Buy211.15%N/A-12.63%-10.31%
RIGL
RIGEL PHARMACEUTICALS INC
$429.63M$24.39$34.8042.68%Buy517.15%111.84%-349.03%36.64%
AXSM
AXSOME THERAPEUTICS INC
$5.31B$109.50$144.5632.01%Strong Buy957.53%N/A738.52%122.19%
VRDN
VIRIDIAN THERAPEUTICS INC
$1.47B$18.51$38.00105.29%Buy7907.34%N/A28.02%25.68%
IRD
OPUS GENETICS INC
$38.51M$1.22$9.00637.70%Strong Buy265.55%N/A-21.17%-17.98%
CRSP
CRISPR THERAPEUTICS AG
$3.47B$40.61$77.7591.46%Buy8139.71%N/A46.42%39.91%
VYGR
VOYAGER THERAPEUTICS INC
$305.90M$5.60$13.96149.20%Strong Buy6-15.21%N/A-0.12%-0.10%
ARGX
ARGENX SE
$39.34B$657.97$684.213.99%Strong Buy14427.28%N/A51.71%45.95%
CAPR
CAPRICOR THERAPEUTICS INC
$651.58M$14.33$41.67190.77%Strong Buy685.22%N/A296.41%217.68%
ARCT
ARCTURUS THERAPEUTICS HOLDINGS INC
$468.34M$17.29$58.00235.45%Strong Buy362.21%N/A132.33%93.49%
SPRO
SPERO THERAPEUTICS INC
$47.05M$0.86$5.00479.37%Buy2-43.64%N/A147.31%71.39%
IFRX
INFLARX NV
$149.56M$2.54$8.00214.96%Buy1795.38%N/A84.72%69.41%
BRTX
BIORESTORATIVE THERAPIES INC
$17.23M$2.49$18.00622.89%Strong Buy1494.43%N/A373.98%256.41%
ALT
ALTIMMUNE INC
$491.47M$6.91$19.00174.96%Strong Buy4938.40%N/A99.05%89.35%
STTK
SHATTUCK LABS INC
$59.20M$1.24$8.67598.95%Hold372.24%N/A-50.91%-44.01%
CMPX
COMPASS THERAPEUTICS INC
$481.56M$3.50$13.75292.86%Strong Buy4502.15%N/A75.95%70.48%
OCUL
OCULAR THERAPEUTIX INC
$1.20B$7.64$18.00135.60%Buy334.98%N/A-2.83%-2.03%
CMRX
CHIMERIX INC
$370.54M$4.12$8.50106.31%Buy2820.67%N/A49.35%42.23%
CLDX
CELLDEX THERAPEUTICS INC
$1.55B$23.29$58.33150.46%Buy674.17%N/A3.71%3.55%
LEGN
LEGEND BIOTECH CORP
$6.62B$36.11$80.33122.47%Strong Buy660.36%N/A174.88%112.45%
EPIX
ESSA PHARMA INC
$75.46M$1.70$2.0017.65%Hold1N/AN/A62.94%61.21%
PRTA
PROTHENA CORP PUBLIC LTD CO
$777.00M$14.44$39.20171.47%Buy535.17%N/A37.12%33.33%
BCYC
BICYCLE THERAPEUTICS PLC
$870.67M$12.61$29.43133.38%Buy729.23%N/A-16.01%-13.35%
ORMP
ORAMED PHARMACEUTICALS INC
$89.09M$2.21N/AN/AN/AN/AN/AN/A-4.90%-4.64%
JANX
JANUX THERAPEUTICS INC
$2.13B$40.68$97.29139.15%Strong Buy7196.07%N/A-24.94%-23.54%
CGON
CG ONCOLOGY INC
$2.03B$30.03$67.67125.33%Strong Buy6473.41%N/A4.91%4.77%
ZVRA
ZEVRA THERAPEUTICS INC
$420.60M$7.88$21.20169.04%Strong Buy5112.22%N/A166.78%60.75%
QSI
QUANTUM-SI INC
$271.15M$1.90$3.2571.05%Buy2202.72%N/A-14.91%-13.28%
AUPH
AURINIA PHARMACEUTICALS INC
$1.16B$8.09$11.5042.15%Strong Buy228.28%N/A54.61%38.57%
TARS
TARSUS PHARMACEUTICALS INC
$2.04B$53.32$58.339.40%Buy371.50%N/A86.76%54.76%
CLGN
COLLPLANT BIOTECHNOLOGIES LTD
$42.56M$3.72$12.50236.38%Strong Buy2257.86%N/A34.53%26.03%
IOVA
IOVANCE BIOTHERAPEUTICS INC
$1.79B$5.88$18.83220.29%Buy3120.31%N/A43.54%33.98%
PMCB
PHARMACYTE BIOTECH INC
$11.08M$1.59N/AN/AN/AN/AN/AN/AN/AN/A
AUTL
AUTOLUS THERAPEUTICS PLC
$558.86M$2.10$10.20385.71%Strong Buy3218.10%N/A25.81%14.88%
FOLD
AMICUS THERAPEUTICS INC
$2.94B$9.83$17.0072.94%Strong Buy722.91%N/A125.32%28.49%
ARQT
ARCUTIS BIOTHERAPEUTICS INC
$1.45B$12.42$18.5048.95%Strong Buy450.20%N/A83.31%29.84%
ARDX
ARDELYX INC
$1.34B$5.67$7.8838.89%Buy432.50%N/A142.89%61.49%
CRGX
CARGO THERAPEUTICS INC
$170.30M$3.70$15.00305.41%Buy5N/AN/A-28.82%-25.62%
RYTM
RHYTHM PHARMACEUTICALS INC
$3.69B$60.01$68.5614.24%Strong Buy970.08%N/A2,868.34%88.48%
KRON
KRONOS BIO INC
$59.74M$0.99$1.6364.14%Buy2N/AN/AN/AN/A
TSHA
TAYSHA GENE THERAPIES INC
$340.21M$1.66$6.60297.59%Strong Buy556.92%N/A-4.62%-2.27%
URGN
UROGEN PHARMA LTD
$462.08M$10.95$42.25285.84%Strong Buy473.21%N/A778.99%65.83%
TECH
BIO-TECHNE CORP
$11.86B$75.01$87.8017.05%Buy56.20%41.84%N/AN/A
SNDX
SYNDAX PHARMACEUTICALS INC
$1.35B$15.82$36.11128.26%Strong Buy9184.88%N/A11.88%10.22%
FENC
FENNEC PHARMACEUTICALS INC
$182.70M$6.66$14.00110.21%Buy246.50%N/A-1,347.47%118.26%
CRVO
CERVOMED INC
$18.41M$2.23$37.601,586.10%Strong Buy5N/AN/AN/AN/A
STOK
STOKE THERAPEUTICS INC
$674.80M$12.74$27.00111.93%Strong Buy374.17%N/A-38.03%-30.10%
NTLA
INTELLIA THERAPEUTICS INC
$1.03B$10.13$44.93343.56%Buy15141.95%N/A66.59%54.63%
MNKD
MANNKIND CORP
$1.56B$5.65$9.7572.57%Strong Buy418.31%56.56%-56.49%25.55%
CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC
$6.21M$3.55N/AN/AN/AN/A1,383.34%N/A169.06%160.93%
MIRM
MIRUM PHARMACEUTICALS INC
$2.46B$51.23$59.8316.79%Strong Buy634.21%N/A133.65%46.43%
SKYE
SKYE BIOSCIENCE INC
$90.41M$2.98$17.25478.86%Strong Buy4N/AN/A-91.65%-85.21%
GNLX
GENELUX CORP
$153.00M$4.43$16.00261.17%Strong Buy32,691.47%N/A89.76%73.76%
VALN
VALNEVA SE
$481.33M$6.93$18.00159.74%Buy138.12%N/A118.22%49.76%
NTRB
NUTRIBAND INC
$74.08M$6.67$13.0094.90%Buy1346.36%N/A361.91%324.07%
ABVX
ABIVAX SA
$379.17M$6.03$33.00447.72%Buy294.03%N/A-124.98%-55.56%
SXTP
60 DEGREES PHARMACEUTICALS INC
$1.22M$0.53N/AN/AN/AN/A60.62%N/A-11.03%-8.98%
MDGL
MADRIGAL PHARMACEUTICALS INC
$7.20B$330.27$369.2911.81%Buy7182.80%N/A130.20%94.28%
PHAR
PHARMING GROUP NV
$601.70M$8.87$27.00204.40%Strong Buy312.40%N/A55.88%29.65%
SPRY
ARS PHARMACEUTICALS INC
$1.24B$12.80$28.33121.35%Strong Buy3377.51%N/A79.06%73.02%
RVMD
REVOLUTION MEDICINES INC
$7.33B$43.57$70.2061.12%Strong Buy10474.74%N/A-22.73%-20.19%
APLS
APELLIS PHARMACEUTICALS INC
$3.76B$30.20$44.6347.76%Buy1619.92%N/A151.52%39.84%
GLYC
GLYCOMIMETICS INC
$17.54M$0.27N/AN/AN/AN/A844.76%N/A-22.67%-16.43%
SWTX
SPRINGWORKS THERAPEUTICS INC
$2.92B$39.28$70.0078.21%Strong Buy484.73%N/A63.13%55.22%

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in Feb 2025?

According to Due Diligence Score, the 3 best biotechnology stocks to buy right now are:

1. Catalyst Pharmaceuticals (NASDAQ:CPRX)


Catalyst Pharmaceuticals (NASDAQ:CPRX) is the top biotech stock with a Due Diligence Score of 76, which is 53 points higher than the biotech industry average of 23. It passed 25 out of 33 due diligence checks and has strong fundamentals. Catalyst Pharmaceuticals has seen its stock return 67.71% over the past year, overperforming other biotech stocks by 100 percentage points.

Catalyst Pharmaceuticals has an average 1 year price target of $32.50, an upside of 40.94% from Catalyst Pharmaceuticals's current stock price of $23.06.

Catalyst Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 6 analysts covering Catalyst Pharmaceuticals, 66.67% have issued a Strong Buy rating, 33.33% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Exelixis (NASDAQ:EXEL)


Exelixis (NASDAQ:EXEL) is the second best biotech stock with a Due Diligence Score of 75, which is 52 points higher than the biotech industry average of 23. It passed 24 out of 33 due diligence checks and has strong fundamentals. Exelixis has seen its stock return 54.24% over the past year, overperforming other biotech stocks by 86 percentage points.

Exelixis has an average 1 year price target of $36.80, an upside of 9.3% from Exelixis's current stock price of $33.67.

Exelixis stock has a consensus Buy recommendation according to Wall Street analysts. Of the 15 analysts covering Exelixis, 40% have issued a Strong Buy rating, 20% have issued a Buy, 40% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Harmony Biosciences Holdings (NASDAQ:HRMY)


Harmony Biosciences Holdings (NASDAQ:HRMY) is the third best biotech stock with a Due Diligence Score of 72, which is 49 points higher than the biotech industry average of 23. It passed 24 out of 33 due diligence checks and has strong fundamentals. Harmony Biosciences Holdings has seen its stock return 23.03% over the past year, overperforming other biotech stocks by 55 percentage points.

Harmony Biosciences Holdings has an average 1 year price target of $56.00, an upside of 44.4% from Harmony Biosciences Holdings's current stock price of $38.78.

Harmony Biosciences Holdings stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Harmony Biosciences Holdings, 28.57% have issued a Strong Buy rating, 71.43% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the biotech stocks with highest dividends?

Out of 3 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

1. Novo Nordisk (Ozempic) (NYSE:NVO)


Novo Nordisk (Ozempic) (NYSE:NVO) has an annual dividend yield of 1.65%, which is 1 percentage points higher than the biotech industry average of 0.69%. Novo Nordisk (Ozempic)'s dividend payout is not stable, having dropped more than 10% nine times in the last 10 years. Novo Nordisk (Ozempic)'s dividend has shown consistent growth over the last 10 years.

Novo Nordisk (Ozempic)'s dividend payout ratio of 45.5% indicates that its dividend yield is sustainable for the long-term.

2. Royalty Pharma (NASDAQ:RPRX)


Royalty Pharma (NASDAQ:RPRX) has an annual dividend yield of 0.67%, which is the same as the biotech industry average of 0.69%. Royalty Pharma's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Royalty Pharma's dividend has shown consistent growth over the last 10 years.

Royalty Pharma's dividend payout ratio of 32.3% indicates that its dividend yield is sustainable for the long-term.

3. Bio Techne (NASDAQ:TECH)


Bio Techne (NASDAQ:TECH) has an annual dividend yield of 0.43%, which is the same as the biotech industry average of 0.69%. Bio Techne's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Bio Techne's dividend has not shown consistent growth over the last 10 years.

Bio Techne's dividend payout ratio of 32% indicates that its dividend yield is sustainable for the long-term.

Why are biotech stocks down?

Biotech stocks were down -1.24% in the last day, and up 0.58% over the last week. Bioxcel Therapeutics was the among the top losers in the biotechnology industry, dropping -37.46% yesterday.

BioXcel Therapeutics shares are trading lower after the company announced a 1-for-16 reverse stock split.

What are the most undervalued biotech stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued biotech stocks right now are:

1. Exelixis (NASDAQ:EXEL)


Exelixis (NASDAQ:EXEL) is the most undervalued biotech stock based on WallStreetZen's Valuation Score. Exelixis has a valuation score of 86, which is 71 points higher than the biotech industry average of 15. It passed 6 out of 7 valuation due diligence checks.

Exelixis's stock has gained 54.24% in the past year. It has overperformed other stocks in the biotech industry by 86 percentage points.

2. Cargo Therapeutics (NASDAQ:CRGX)


Cargo Therapeutics (NASDAQ:CRGX) is the second most undervalued biotech stock based on WallStreetZen's Valuation Score. Cargo Therapeutics has a valuation score of 71, which is 56 points higher than the biotech industry average of 15. It passed 5 out of 7 valuation due diligence checks.

Cargo Therapeutics's stock has dropped -83.87% in the past year. It has underperformed other stocks in the biotech industry by -52 percentage points.

3. Harmony Biosciences Holdings (NASDAQ:HRMY)


Harmony Biosciences Holdings (NASDAQ:HRMY) is the third most undervalued biotech stock based on WallStreetZen's Valuation Score. Harmony Biosciences Holdings has a valuation score of 71, which is 56 points higher than the biotech industry average of 15. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 23.03% in the past year. It has overperformed other stocks in the biotech industry by 55 percentage points.

Are biotech stocks a good buy now?

55.08% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 91.2% over the next year.

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is -152.12x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.